Skip to main content
MyDeficiencies

Ethosuximide

Succinimide anticonvulsant

Also sold as Zarontin.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Ethosuximide has almost none of the classical depletion machinery this dossier series is built to catch, and that absence is itself the headline. Its hepatic metabolism runs through CYP3A4 and CYP2E1, but ethosuximide is documented as a non-enzyme-inducing anticonvulsant: a 2005 best-practice guideline on epilepsy in women of reproductive age explicitly classifies it that way, in direct contrast to phenytoin, primidone, and phenobarbital, the enzyme-inducing anticonvulsants reviewed elsewhere in this project whose vitamin D, folate, and vitamin K depletion signals all trace back to accelerated hepatic catabolism via induced CYP450 enzymes. That specific machine is not present in ethosuximide's own pharmacology. Roughly 20% of a dose is excreted unchanged in the urine, oral bioavailability is high (approximately 93%), and no documented absorption-interference, renal-tubular-wasting, or mineral/antacid interaction mechanism was found for this drug despite a genuine search. The succinimide structure and T-type calcium channel mechanism that defines ethosuximide's antiseizure effect are distinct from the sodium-channel and enzyme-induction pharmacology of the older hydantoin and barbiturate-class anticonvulsants, and this dossier does not assume the classic AED depletion pattern transfers across that line.

Succinimide anticonvulsant · ATC N03AD01 · also sold as Zarontin · reviewed 2026-10-02. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Ethosuximide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Red tier

Red — Severe

See study details

No nutrient or category in this dossier reached red.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Empty

Limits on what this shows

  • What would fill this tier: Two or more independent human studies, each with ethosuximide-treated patients in the cohort, directly measuring a nutrient or validated functional marker, with consistent direction and a named mechanism.

Why empty

Red requires at least two independent Tier A drug-specific sources with the nutrient directly measured. Ethosuximide's own pharmacokinetic profile, non-enzyme-inducing, no documented absorption interference, no documented renal-tubular wasting, gives no classical mechanism to search a nutrient against in the first place, and the genuine and tooling-limited gaps across the seven mandatory categories (below) mean no Tier A human dataset measuring any of them was located this session either.

Orange tier

Red — Severe

See study details

No nutrient or category in this dossier reached orange.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Empty

Limits on what this shows

  • What would fill this tier: A Tier A, ethosuximide-specific human study directly measuring a nutrient and finding a real but bounded deficit, for example limited to a defined exposure window or subgroup.

Why empty

Orange requires at least one Tier A drug-specific source showing a real, bounded deficit. The one Tier A, drug-specific, nutrient-adjacent finding located this session, the label's blood-dyscrasia warning, is a direct hematologic toxicity rather than a nutrient-mediated deficit (Hard Rule 2) and is written up in the Monitoring panel, not graded here.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

See study details

No grade assigned: no confirmed Tier B/C ethosuximide-specific evidence, and no circulating consumer claim located to rebut.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Ethosuximide's own target, T-type calcium channel blockade, is its intended neuronal pharmacology, not a mitochondrial mechanism, and is excluded from grading here under Hard Rule 2 regardless. The candidate review, "Effects of antiepileptic drugs on mitochondrial functions, morphology, kinetics, biogenesis, and survival" (Finsterer & Scorza, 2017, PMID 28732239), was reached this revision via OpenAlex's single-record lookup, which returned its title, authors, and full indexed keyword/concept list (mitochondrion, mitochondrial biogenesis, mitochondrial respiratory chain, mitochondrial toxicity, mitochondrial disease, lamotrigine, valproic acid, carbamazepine, levetiracetam) but no abstract text (not indexed by the source). No ethosuximide or succinimide keyword appears anywhere in that list, indicating the review's actual coverage is the drugs named, not ethosuximide; it still cannot be cited as support, now with higher confidence that it specifically excludes this drug rather than merely being inaccessible. No circulating consumer claim specifically linking ethosuximide to mitochondrial damage was located. The dual condition for ungraded (Step 7) is met.

Channels tried

OpenAlex single-record lookup (api.openalex.org/works/pmid:28732239): succeeded this revision, returning the metadata described above (no abstract). Europe PMC article page (europepmc.org/article/MED/28732239): blocked by that host's own robots.txt rules this revision. PubMed search-listing pages (multiple phrasings, both the original review and this revision): 429/rate-limit responses on every attempt this revision. OpenAlex bulk search endpoint: 429. Semantic Scholar graph API: 429 this revision (consistent with the original review). Bing and DuckDuckGo search-results pages: both disallowed by their own robots.txt rules to this session's fetch tooling. scholar.archive.org: rate-limited. DailyMed/FDA label: contains no mitochondrial-function language. General WebSearch: unavailable both in the original review (budget exhausted) and this revision (same session-wide budget already exhausted at the time this category was re-run).

Assessment

Mixed, but firmer than the original review. The Finsterer & Scorza source is now confirmed, via its own indexed keywords, not to cover ethosuximide, so it is ruled out rather than merely inaccessible. No alternative ethosuximide-specific mitochondrial source was found despite a wide range of channels tried across two sessions, and most of those channels (PubMed, Europe PMC, OpenAlex bulk search, Semantic Scholar, Bing, DuckDuckGo) remain blocked, so a genuine literature gap cannot yet be distinguished with confidence from a tooling-limited one for this category as a whole.

  • Finsterer J, Scorza FA. Effects of antiepileptic drugs on mitochondrial functions, morphology, kinetics, biogenesis, and survival. 2017. — Review. Metadata opened and read this revision via OpenAlex's single-record PMID lookup (api.openalex.org/works/pmid:28732239): title, authors, and full indexed keyword/concept list confirmed (mitochondrion, mitochondrial biogenesis, mitochondrial respiratory chain, mitochondrial toxicity, mitochondrial disease, lamotrigine, valproic acid, carbamazepine, levetiracetam); no ethosuximide or succinimide keyword present. Abstract text itself is not indexed by the source and was not obtained. Access note: metadata confirmed open this revision; full abstract/text not accessible (europepmc.org article page disallowed by robots.txt this revision; PubMed article-detail page bot-verification-walled in the original review). Keyword evidence indicates this review is not stratified to ethosuximide. Not used as support for any grade; see Mitochondrial burden and Oxidative stress entries.Access note: metadata confirmed open this revision; full abstract/text not accessible (europepmc.org article page disallowed by robots.txt this revision; PubMed article-detail page bot-verification-walled in the original review). Keyword evidence indicates this review is not stratified to ethosuximide. Not used as support for any grade; see Mitochondrial burden and Oxidative stress entries.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Not graded — disclosed evidence gap

See study details

No grade assigned: no confirmed Tier B/C ethosuximide-specific evidence, and no circulating consumer claim located to rebut.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A completed PubMed search for "ethosuximide oxidative stress" returned six results. None measured an oxidative-stress or antioxidant-capacity marker in ethosuximide-treated subjects. One, a 2025 medicinal-chemistry paper on novel Nrf2-ARE-activating anticonvulsant candidates, used ethosuximide only as a potency comparator in what is most likely a standard seizure-threshold assay (MES/PTZ-type), not an oxidative-stress measurement of ethosuximide itself; its full text could not be opened this session to confirm what role ethosuximide played, so it is not used as support. No circulating consumer claim specifically linking ethosuximide to oxidative stress or antioxidant depletion was located. The dual condition for ungraded (Step 7) is met.

Channels tried

PubMed search-listing page, "ethosuximide oxidative stress": completed successfully in the original review, 6 results reviewed by title and available snippet, none ethosuximide-specific for this category. Follow-up attempt to open the Nrf2-ARE paper's (PMID 40088686) article-detail page to confirm ethosuximide's exact role: not attempted separately given the bot-verification wall confirmed on other PubMed article-detail pages. This revision re-attempted PubMed (429 on every attempt), Europe PMC's REST API (429), OpenAlex's bulk search endpoint (429), the Semantic Scholar web search UI and API (robots-disallowed and 429 respectively), and Bing and DuckDuckGo search-results pages (both robots-disallowed to this session's fetch tooling). DailyMed/FDA label: no oxidative-stress or antioxidant language. General WebSearch: unavailable in both sessions (budget exhausted).

Assessment

Mixed, now confirmed across two sessions. The completed PubMed search itself is a genuine result (no drug-specific hit), but the one borderline candidate (the Nrf2-ARE comparator paper) could still not be fully checked, and every other channel attempted this revision was blocked again, matching the original review's pattern closely enough that the blocking looks systemic rather than a one-off; still worth re-checking once any of these hosts recovers.

  • Abd-Allah WH, et al. Design and synthesis of novel cyclohexanecarboxamides with anticonvulsant effect by activating Nrf2-ARE pathway. 2025. — Medicinal-chemistry study of novel anticonvulsant candidates; uses ethosuximide as a comparator compound Access note: search-listing snippet only; ethosuximide's exact role (likely a seizure-threshold-assay comparator, not an oxidative-stress subject) could not be independently confirmed this session. Not used as support for any grade; see Oxidative stress entry.Access note: search-listing snippet only; ethosuximide's exact role (likely a seizure-threshold-assay comparator, not an oxidative-stress subject) could not be independently confirmed this session. Not used as support for any grade; see Oxidative stress entry.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No grade assigned: no mechanism identified, no confirmed evidence at any tier, and no circulating consumer claim located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism was identified at Step 2 connecting ethosuximide's pharmacology to copper handling (no chelation, no ceruloplasmin or copper-dependent enzyme interaction described anywhere in sources opened this session). No Tier B or Tier C evidence was confirmed, and no circulating consumer claim about ethosuximide and copper was found to rebut as white. The dual condition for ungraded (Step 7) is met, though the search itself was repeatedly blocked rather than cleanly completed (see below).

Channels tried

PubMed search-listing page, "ethosuximide copper": attempted three separate times in the original review (60-120 second waits between attempts; 429, 429, then a reCAPTCHA bot-verification page), and attempted twice more this revision (after 45- and 90-second waits), both again returning 429. Never successfully completed across either session. Europe PMC REST API: 429 in the original review. Crossref works API: 429/403 (also logged at the proxy level as a policy-denied connection to api.crossref.org). OpenAlex bulk search endpoint: 429 in both sessions. OpenAlex single-record lookup: not usable here since no candidate PMID for this term was ever surfaced. Semantic Scholar API: 429. Bing and DuckDuckGo search-results pages: both disallowed by their own robots.txt rules to this session's fetch tooling this revision. DailyMed/FDA label: no mention of copper or ceruloplasmin. General WebSearch: unavailable in both sessions (budget exhausted).

Assessment

Tooling-limited, not a confirmed clean gap, and now confirmed across two separate sessions and five-plus PubMed attempts. Unlike Iron (below), no search for this specific term has ever been allowed to complete on any channel. This remains the single highest-priority category to re-run once any of these hosts recovers.

Iron

Not graded — disclosed evidence gap

See study details

No grade assigned: a completed, successful search returned no ethosuximide-specific evidence, and no circulating consumer claim was located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism was identified at Step 2 connecting ethosuximide's pharmacology to iron absorption, transport, or storage. A completed PubMed search returned two results, neither drug-specific: a 2025 review on calcium-iron crosstalk in epileptogenesis generally (not an ethosuximide study), and a 2007 rat model of iron-induced cortical seizures (an iron-induced seizure model, not an ethosuximide-iron interaction study). No circulating consumer claim about ethosuximide and iron was located. The dual condition for ungraded (Step 7) is met on a genuinely completed search.

Channels tried

PubMed search-listing page, "ethosuximide iron": completed successfully on the first attempt in the original review, 2 results reviewed in full by title, authors, year, and available snippet; neither ethosuximide-specific. Europe PMC, Crossref, Semantic Scholar, OpenAlex bulk search: not separately re-run for this exact term, given the PubMed search itself completed cleanly and the pattern of 429 responses on these hosts was already well established for adjacent queries. This revision re-confirmed the general PubMed access pattern rather than re-running this exact term again (the host was 429-blocked on the specific queries re-attempted this revision, for other categories); the original clean result stands unchanged. DailyMed/FDA label: no mention of iron, ferritin, or transferrin. General WebSearch: unavailable in both sessions (budget exhausted).

Assessment

Most likely a genuine literature gap rather than a tooling failure: this remains the one mandatory category where the primary search channel (PubMed) actually completed and returned a clean, reviewable result set with no drug-specific hit, consistent with the absence of any iron-relevant mechanism in ethosuximide's own pharmacokinetic profile.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, animal donor-model finding only

Yellow — Low

See study details

In an animal fecal-microbiota-transplant (FMT) study, ethosuximide treatment measurably shifted the gut microbiota of treated donor rats; no human gut-microbiome data on ethosuximide was located in any source opened this session.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None located specific to the ethosuximide-donor arm; no second, independent study replicating this finding was located this revision (see Channels tried).
  • At-risk subgroups: Not established in humans. This is a single animal study with no clinical population data and no dose-response information.

Regulatory status

Ethosuximide's FDA label (DailyMed) contains no statement on gut microbiome or intestinal effects. This entry rests entirely on one animal study, not the label.

Population evidence

Citraro R, et al. Epilepsia. 2021; DOI 10.1111/epi.16813, PMID 33428780. Animal study (rat), not human. Non-epileptic Wistar rats were either left untreated or treated with ethosuximide (ETH) at 6 months of age, then used as fecal-microbiota-transplant donors into WAG/Rij rats (a genetic absence-epilepsy model), with EEG monitored over 4 weeks post-transplant. The same paper separately compared baseline gut microbiota and intestinal histology in WAG/Rij versus Wistar rats at 1, 4, and 8 months; that disease-model-versus-healthy-strain comparison is confounded by indication (Hard Rule 6, absence epilepsy itself, not the drug) and is explicitly NOT the basis of this entry's claim. The drug-specific finding is the donor-arm comparison: the abstract, reconstructed via OpenAlex this revision (full text sits behind a Wiley paywall and could not be opened), reports significant differences in beta diversity and in the Bacteroidetes/Firmicutes ratio between the untreated and ETH-treated donor conditions, and states that FMT reduced seizure frequency/duration and partially restored intestinal histology in WAG/Rij recipients. The abstract alone does not resolve whether the ETH-treated-donor arm's shift was more or less favorable than the untreated-donor arm's, only that ethosuximide treatment produced a measurable, distinct microbiota signature in the donor rats, independent of the epilepsy model.

Mechanism

Named: direct gut-microbiome alteration by the drug itself (Step 2 mechanism G), demonstrated in ethosuximide-treated donor animals that were not themselves epileptic, isolating a drug effect from the disease-intrinsic WAG/Rij-versus-Wistar comparison in the same paper.

Channels tried this revision

OpenAlex single-record PMID lookup (api.openalex.org/works/pmid:33428780): succeeded, returning a full reconstructed abstract that confirms ethosuximide-treated donor rats were part of the study design, resolving the cohort-test question this category was ungraded for in the prior review. Europe PMC article page (europepmc.org/article/MED/33428780): blocked by that host's own robots.txt rules as seen by this session's fetch tooling. Attempts to reach the full text via the DOI landing page, OpenAlex's bulk search, Semantic Scholar, Bing, DuckDuckGo, and scholar.archive.org all failed (429 responses, robots-disallowed pages, or an archive.org rate limit); see the dossier-wide access note. This entry is graded on the confirmed abstract only.

Counter-evidence held on record

Counter-evidence / limits One animal study, donor-arm comparison only, with no human replication, no dose-response data, and no independently opened full text. The direction of the ethosuximide-specific microbiota shift (more or less diverse or favorable than the untreated-donor arm) could not be confirmed from the abstract alone. A separate 2026 randomized clinical trial of ethosuximide for irritable-bowel-syndrome-related abdominal pain (Kerckhove et al.) reports only a tolerability finding (higher discontinuation than comparators), not a microbiome-composition measurement, and does not add human evidence to this entry either way. Framing caution: animal, donor-rat evidence only. This does not establish a gut-microbiome effect in ethosuximide-treated epilepsy patients and is not a basis for any probiotic, prebiotic, or dietary change.

  • Citraro R, et al. First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia. 2021. DOI 10.1111/epi.16813. — Animal-model (rat) study. Full abstract opened and read this revision via OpenAlex's single-record PMID lookup (api.openalex.org/works/pmid:33428780), which reconstructed the complete abstract text from the publication's indexed abstract. Confirms non-epileptic Wistar rats were either left untreated or treated with ethosuximide (ETH) and used as fecal-microbiota-transplant donors into WAG/Rij rats; reports significant differences in beta diversity and Bacteroidetes/Firmicutes ratio between the two donor conditions. Used as support for the Gut microbiome risk entry (yellow), the only entry in this dossier resting on this source. Access note: abstract confirmed open and read via OpenAlex this revision; full text (Wiley, behind the DOI) was not opened. The europepmc.org article page was disallowed by that host's robots.txt this revision.Access note: abstract confirmed open and read via OpenAlex this revision; full text (Wiley, behind the DOI) was not opened. The europepmc.org article page was disallowed by that host's robots.txt this revision.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No grade assigned for a nutrient-mediated oxygen-delivery deficiency. Ethosuximide's own label documents a real, Tier A, drug-specific hematologic adverse effect, but it is a direct toxicity, not nutrient depletion, and is not graded here.

Full detail, limits and 3 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Ethosuximide's FDA label states that blood dyscrasias, including some with fatal outcome, have been reported, with periodic blood counts recommended; this is consistent with the known succinimide-class risk of leukopenia, agranulocytosis, pancytopenia, eosinophilia, and rare aplastic anemia. This revision located and read, by title, author, year, and PMID, three independent ethosuximide-specific case reports of aplastic anemia (1994, 1983, and a 2025 report attributing the mechanism to drug-induced lupus erythematosus), which corroborate the label's own warning with named primary sources rather than the label alone. That is still a direct bone-marrow toxicity, not evidence that ethosuximide depletes iron, copper, B12, or any other nutrient required for erythropoiesis, and grading it as a nutrient-mediated oxygen-delivery deficiency would violate the rule against filing a drug's own adverse effect as a deficiency finding (the same logic the protocol applies to a beta-blocker's intended heart-rate reduction, applied here to an idiosyncratic toxicity instead of an intended effect). No study measuring hemoglobin, hematocrit, or red-cell mass specifically as a function of nutrient status in ethosuximide-treated patients was located, and no circulating consumer claim linking ethosuximide to "low oxygen" or "low energy" via a blood-nutrient pathway was located to rebut as white. The dual condition for ungraded (Step 7), applied to the nutrient-mediated version of this category specifically, is met on the evidence confirmed open and readable.

Channels tried

FDA-approved structured product label via DailyMed: this is the source of the blood-dyscrasia finding above. A dedicated PubMed search combining ethosuximide with hemoglobin/anemia/hematocrit terms was attempted in the original review as part of a combined query ("ethosuximide AND (folate OR folic acid OR vitamin B12 OR zinc OR biotin OR hemoglobin OR anemia)"); it completed and returned ten class-wide AED-review results, none isolating ethosuximide's hematologic/nutrient profile specifically. This revision ran a cleaner, narrower PubMed query, "ethosuximide hemoglobin OR ethosuximide anemia OR ethosuximide erythropoiesis," which completed successfully and returned 13 results, including the three ethosuximide-specific aplastic-anemia case reports now cited above (PMID 7986296, PMID 6424403, PMID 40013843) plus several class-wide AED safety-monitoring reviews. None of these, including the case reports, measure a nutrient or functional marker; all describe the toxicity itself, consistent with Hard Rule 2. Europe PMC, Crossref, Semantic Scholar, OpenAlex bulk search: 429 on attempts made for adjacent queries. General WebSearch: unavailable in both sessions (budget exhausted).

Assessment

The nutrient-mediated version of this category is most likely a genuine gap, consistent with the mechanism screen (no iron, copper, or B12 pathway implicated anywhere in ethosuximide's pharmacology) and now backed by a completed, successful search that surfaced only toxicity case reports, never a nutrient-status measurement. The real, Tier A finding, bone-marrow suppression, is disclosed, now with named case-report corroboration, and routed to the Monitoring panel instead of graded here, per Hard Rule 2.

  • Shahar E, et al. Aplastic anemia following therapy for absence seizures with ethosuximide. 1994. — Case report, ethosuximide specifically named. Found and read this revision via a completed PubMed search-listing page ("ethosuximide hemoglobin OR ethosuximide anemia OR ethosuximide erythropoiesis"). Describes a direct hematologic toxicity, not a nutrient-status finding; used only to corroborate the label's blood-dyscrasia warning in the Monitoring panel, per Hard Rule 2, not graded as a nutrient entry.
  • Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone. 1983. — Case report, ethosuximide specifically named. Found and read this revision via the same completed PubMed search as above. Same use and limitation as the Shahar et al. 1994 case report.
  • Ethosuximide-associated Aplastic Anemia Likely Due to Drug-induced Lupus Erythematosus: A Case Report With Immunologic Insights. 2025. — Case report, ethosuximide specifically named, proposing a drug-induced-lupus mechanism for the bone-marrow toxicity. Found and read this revision via the same completed PubMed search as above. Same use and limitation as the other two aplastic-anemia case reports.

ATP production

Not graded — disclosed evidence gap

See study details

No grade assigned: no confirmed Tier B/C ethosuximide-specific evidence on cellular ATP synthesis, and no circulating consumer claim located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism was identified at Step 2 connecting ethosuximide's T-type calcium channel pharmacology to mitochondrial ATP synthesis specifically; that target is neuronal and intended (Hard Rule 2), not a stated effect on cellular energy metabolism generally. No Tier B or Tier C ethosuximide-specific study on ATP production was confirmed open and readable this session (a dedicated search was blocked before returning results; see below), and no circulating consumer "low energy"/ATP claim specifically naming ethosuximide was located to rebut as white. The dual condition for ungraded (Step 7) is met on the evidence actually confirmed, though the underlying search itself was not allowed to complete (see Assessment).

Channels tried

PubMed search-listing page, "ethosuximide mitochondrial ATP": attempted twice in the original review (429, then a reCAPTCHA bot-verification page). A broader combined query returned a malformed, essentially unfiltered result set and is not treated as a valid attempt. This revision additionally attempted PubMed again (429), OpenAlex's bulk search endpoint (429), the Semantic Scholar web search UI (robots-disallowed) and API (429), and Bing and DuckDuckGo search-results pages (both robots-disallowed to this session's fetch tooling). Europe PMC, Crossref: 429 in the original review. DailyMed/FDA label: no ATP or energy-metabolism language. General WebSearch: unavailable in both sessions (budget exhausted).

Assessment

Tooling-limited, not a confirmed clean gap, now across two sessions. This category's dedicated search has never been allowed to complete on any channel; it remains the second priority (after Copper) to re-run once any of these hosts recovers.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Vitamin D

    Where it comes from: Class-wide anticonvulsant-and-bone-health literature. A PubMed search for "ethosuximide vitamin D" returned six results; all concern phenytoin, valproate, or anticonvulsants generally (osteoporosis/rickets/bone-density reviews), and none isolate ethosuximide. This is the same literature base that supports a real, Tier A/B finding for enzyme-inducing anticonvulsants in this project's sibling dossiers.

    Why it fails: The mechanism these sources invoke is accelerated hepatic catabolism of vitamin D via CYP450 enzyme induction. Ethosuximide is specifically documented as a non-enzyme-inducing anticonvulsant (see Pharmacokinetic basis); the one mechanism that would support this claim is affirmatively absent from ethosuximide's own pharmacology. No ethosuximide-specific study measuring vitamin D status was located despite a direct search. This is this drug's own chemistry ruling the mechanism out, not merely "unproven for this drug specifically."

  • Folate (folic acid)

    Where it comes from: Class-wide anticonvulsant-neuropsychiatric literature. Two reviews located this session, Reynolds & Trimble (1985) and a 2025 review on psychiatric/behavioral anticonvulsant side effects (Lyndon et al.), both reference "folic acid metabolism" disturbance or "folate depletion" as a contributing mechanism to anticonvulsant neuropsychiatric effects; neither isolates ethosuximide in the retrievable search-listing snippet, and their full text could not be opened this session to confirm cohort composition.

    Why it fails: As with vitamin D, the classical mechanism for anticonvulsant-associated folate depletion is accelerated catabolism via CYP450 induction, a mechanism ethosuximide's own pharmacokinetic profile rules out. No ethosuximide-specific study measuring folate status was located. Because the source reviews' full text could not be opened, their cohort could not be independently re-confirmed this session (disclosed as a partial verification); the rebuttal rests primarily on ethosuximide's own Step 1 pharmacokinetic finding, not on having excluded ethosuximide from those two reviews' cohorts directly.

How the body handles this medication

Metabolism
Hepatic, predominantly via CYP3A4 and CYP2E1-mediated hydroxylation to inactive metabolites (further conjugated for excretion); the drug is not appreciably metabolized by a single dominant pathway in the way some AEDs are.DrugBank-sourced pharmacokinetic synthesis (secondary source, see access note); Wikipedia, Ethosuximide, citing DrugBank DB00593
CYP450 induction/inhibition
Classified as a non-enzyme-inducing anticonvulsant in a best-practice epilepsy guideline opened this session; no clinically significant CYP450 induction or inhibition by ethosuximide itself was found in any source opened this session. This is the single most important fact in this dossier: it is the mechanism (Step 2, mechanism B) that drives the classical AED-vitamin D/folate/vitamin K depletion pattern seen with phenytoin, primidone, and phenobarbital, and it is absent here.Crawford P. Best practice guidelines for the management of women with epilepsy. Seizure. 2005;14(3):212-213. PMID 16302885 (PubMed search-listing snippet)
Elimination
Approximately 20% of a dose is excreted unchanged in the urine; the remainder is excreted as metabolites, predominantly renal. Elimination half-life is documented at approximately 53 hours. No renal-tubular-wasting mechanism (Step 2, mechanism C) was found in any source opened this session.Wikipedia, Ethosuximide, citing DrugBank DB00593 (secondary source, see access note)
Absorption
Oral bioavailability approximately 93%; no transporter-mediated, pH-dependent, or chelation-based absorption-interference mechanism (Step 2, mechanism A) was found despite a direct search for food/mineral/antacid interactions.Wikipedia, Ethosuximide, citing DrugBank DB00593 (secondary source, see access note)
Drug-drug interactions (direction: other-drug-affecting, not nutrient)
Ethosuximide may elevate serum phenytoin levels; valproic acid can increase or decrease ethosuximide levels (bidirectional). Per Hard Rule 4, this is a timing/monitoring interaction between two drugs, not a nutrient-depletion mechanism, and is not graded here.FDA-approved structured product label, Zarontin (ethosuximide), via DailyMed, setid 0e008f33-70a1-4bc6-b3a0-d45214418ab6
Hepatic/renal caution and hematologic warning
The label states abnormal liver and renal function studies have been reported and recommends extreme caution in patients with known liver or renal disease; it also states blood dyscrasias, including some with fatal outcome, have been reported, with periodic blood counts recommended. These are the drug's own documented adverse effects (Hard Rule 2), not nutrient deficiencies; see Monitoring panel.FDA-approved structured product label, Zarontin (ethosuximide), via DailyMed, setid 0e008f33-70a1-4bc6-b3a0-d45214418ab6

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Hematologic

    Periodic blood counts

    Ethosuximide's own label reports blood dyscrasias, including rare fatal outcomes (leukopenia, agranulocytosis, pancytopenia, eosinophilia); periodic CBC monitoring is recommended. Three independent published case reports of ethosuximide-associated aplastic anemia corroborate this. This is a direct drug toxicity, not a nutrient deficiency, and no supplement addresses it.

  • Hepatic / renal

    Liver and renal function panels

    Abnormal liver and renal function studies have been reported; the label recommends extreme caution, with periodic monitoring, in patients with known hepatic or renal disease, where accumulation is more likely given the drug's long half-life.

  • Drug interaction

    Phenytoin and valproic acid levels

    Ethosuximide may elevate serum phenytoin levels; valproic acid can increase or decrease ethosuximide levels. Periodic serum level determinations are recommended when these drugs are co-administered. Not a nutrient-timing interaction; included because it is the one labeled interaction ethosuximide carries.

  • General

    No preemptive supplementation

    No entry in this dossier reaches a tier that supports a dosing recommendation. The one yellow entry (gut microbiome risk) rests on a single animal study and is barred from a dosing recommendation like every yellow tier; the two classical-nutrient entries (vitamin D, folate) are graded white specifically because this drug's own chemistry rules out the mechanism that would otherwise support them; the remaining six categories are ungraded. Yellow, white, and ungraded tiers are all barred from dosing recommendations by design.

  • Research re-check priority

    Categories to re-run when tooling recovers

    Copper and ATP production (dedicated searches never completed on any channel across two sessions), and Mitochondrial burden and Oxidative stress (one candidate source each found, but now confirmed not to cover ethosuximide, or only partially checked). Gut microbiome risk was resolved this revision via OpenAlex's single-record lookup and no longer needs re-checking at this priority. Re-check PubMed, Europe PMC, Crossref, Semantic Scholar, OpenAlex's bulk search endpoint, and general web search first, since those remain the channels blocked across both sessions rather than cleanly exhausted.

Overlap map, to prevent double counting

  • Vitamin D (Fails verification)

    Shares evidence with: Folate (Fails verification)

    Note: Both rebuttals rest on the same single Pharmacokinetic Basis fact: ethosuximide's documented status as a non-enzyme-inducing anticonvulsant. This is one mechanism-absence argument applied twice, not two independent confirmations that ethosuximide is nutrient-safe.

  • Oxygen delivery/utilization (ungraded)

    Shares evidence with: Monitoring panel, "Blood counts" card; Sources [the three aplastic-anemia case reports]

    Note: All derive from the same underlying toxicity signal: the FDA label's blood-dyscrasia warning, now corroborated by three named ethosuximide-specific case reports found this revision. The fact is disclosed once as a toxicity-monitoring item across these locations; it is not independent nutrient evidence and must not be read as such in any of them.

  • Mitochondrial burden (ungraded)

    Shares evidence with: Oxidative stress (ungraded)

    Note: Both entries' "why no grade" discussion references the same unconfirmed candidate source, Finsterer & Scorza 2017, found via the same PubMed search for "ethosuximide oxidative stress." It is explicitly not used as support in either entry; naming it in both places is a shared disclosure of the same inaccessible source, not two separate pieces of evidence.

  • Vitamin D / Folate (Fails verification)

    Shares evidence with: Sibling anticonvulsant dossiers in this project (phenytoin, primidone, phenobarbital)

    Note: The class-wide source material behind these two circulating claims (enzyme-induction-mediated AED nutrient depletion, including the Reynolds & Trimble 1985 and Crawford 2005 reviews) is shared raw material across this project's anticonvulsant batch. For the enzyme-inducing siblings, that same mechanism is present and the finding is not rebutted; a reader must not average ethosuximide's white verdict here against those drugs' different, non-rebutted grade, or treat one review as having separately "cleared" every anticonvulsant it mentions.

All references used above
  1. Zarontin (ethosuximide), FDA-approved structured product label — Capsule and solution labeling (Parke-Davis/Pfizer); Warnings, Precautions, and Drug Interactions sections read directly, twice, early in this sessionAccess note: this label's own Clinical Pharmacology section contains minimal PK detail (no stated metabolism/CYP/half-life/protein-binding figures); those parameters are sourced from DrugBank via the secondary synthesis below. Later same-session attempts to re-fetch this page for additional label text returned 429 rate-limit responses.
  2. Crawford P. Best practice guidelines for the management of women with epilepsy. Seizure. 2005;14(3):212-213. — Clinical practice guideline; PMID 16302885, explicitly classifies ethosuximide as "nonenzyme-inducing" Access note: opened as a PubMed search-listing snippet only; the full article-detail page was not independently opened this session.Access note: opened as a PubMed search-listing snippet only; the full article-detail page was not independently opened this session.
  3. Reynolds EH, Trimble MR. Adverse neuropsychiatric effects of anticonvulsant drugs. Drugs. 1985;29(6):570-581. — Narrative review, not stratified by drug in the retrievable snippet; references "disturbance of folic acid...metabolism" as a class-wide mechanism Access note: PubMed search-listing snippet only; cohort for ethosuximide specifically not confirmed. Tier C for ethosuximide; cited only as the origin of the Folate circulating claim, not as supporting evidence.Access note: PubMed search-listing snippet only; cohort for ethosuximide specifically not confirmed. Tier C for ethosuximide; cited only as the origin of the Folate circulating claim, not as supporting evidence.
  4. Lyndon S, Dworetzky BA, Baslet G. Psychiatric and behavioural side effects of antiseizure medications in epilepsy. 2025. — Review; retrievable snippet references "folate depletion" as a contributor to psychiatric/behavioral antiseizure-medication side effects, not stratified to ethosuximide Access note: PubMed search-listing snippet only. Tier C for ethosuximide; cited only as the origin of the Folate circulating claim, not as supporting evidence.Access note: PubMed search-listing snippet only. Tier C for ethosuximide; cited only as the origin of the Folate circulating claim, not as supporting evidence.
  5. Strzelczyk A, Schubert-Bast S. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications. CNS Drugs. 2022;36(10):1079-1111. — Review; lists ethosuximide among medications reviewed; no nutrient-specific finding in the retrievable snippet Access note: PubMed search-listing snippet only; not used as support for any grade.Access note: PubMed search-listing snippet only; not used as support for any grade.
  6. Citraro R, et al. First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia. 2021. DOI 10.1111/epi.16813. — Animal-model (rat) study. Full abstract opened and read this revision via OpenAlex's single-record PMID lookup (api.openalex.org/works/pmid:33428780), which reconstructed the complete abstract text from the publication's indexed abstract. Confirms non-epileptic Wistar rats were either left untreated or treated with ethosuximide (ETH) and used as fecal-microbiota-transplant donors into WAG/Rij rats; reports significant differences in beta diversity and Bacteroidetes/Firmicutes ratio between the two donor conditions. Used as support for the Gut microbiome risk entry (yellow), the only entry in this dossier resting on this source. Access note: abstract confirmed open and read via OpenAlex this revision; full text (Wiley, behind the DOI) was not opened. The europepmc.org article page was disallowed by that host's robots.txt this revision.Access note: abstract confirmed open and read via OpenAlex this revision; full text (Wiley, behind the DOI) was not opened. The europepmc.org article page was disallowed by that host's robots.txt this revision.
  7. Kerckhove N, et al. Ethosuximide and Irritable Bowel Syndrome-Related Abdominal Pain: A Randomized Clinical Trial. 2026. — Randomized clinical trial repurposing ethosuximide for IBS-related abdominal pain; retrievable snippet reports ethosuximide "was less well tolerated, with higher discontinuation rates" than comparators (a tolerability finding, not a microbiome-composition measurement)
  8. Finsterer J, Scorza FA. Effects of antiepileptic drugs on mitochondrial functions, morphology, kinetics, biogenesis, and survival. 2017. — Review. Metadata opened and read this revision via OpenAlex's single-record PMID lookup (api.openalex.org/works/pmid:28732239): title, authors, and full indexed keyword/concept list confirmed (mitochondrion, mitochondrial biogenesis, mitochondrial respiratory chain, mitochondrial toxicity, mitochondrial disease, lamotrigine, valproic acid, carbamazepine, levetiracetam); no ethosuximide or succinimide keyword present. Abstract text itself is not indexed by the source and was not obtained. Access note: metadata confirmed open this revision; full abstract/text not accessible (europepmc.org article page disallowed by robots.txt this revision; PubMed article-detail page bot-verification-walled in the original review). Keyword evidence indicates this review is not stratified to ethosuximide. Not used as support for any grade; see Mitochondrial burden and Oxidative stress entries.Access note: metadata confirmed open this revision; full abstract/text not accessible (europepmc.org article page disallowed by robots.txt this revision; PubMed article-detail page bot-verification-walled in the original review). Keyword evidence indicates this review is not stratified to ethosuximide. Not used as support for any grade; see Mitochondrial burden and Oxidative stress entries.
  9. Abd-Allah WH, et al. Design and synthesis of novel cyclohexanecarboxamides with anticonvulsant effect by activating Nrf2-ARE pathway. 2025. — Medicinal-chemistry study of novel anticonvulsant candidates; uses ethosuximide as a comparator compound Access note: search-listing snippet only; ethosuximide's exact role (likely a seizure-threshold-assay comparator, not an oxidative-stress subject) could not be independently confirmed this session. Not used as support for any grade; see Oxidative stress entry.Access note: search-listing snippet only; ethosuximide's exact role (likely a seizure-threshold-assay comparator, not an oxidative-stress subject) could not be independently confirmed this session. Not used as support for any grade; see Oxidative stress entry.
  10. Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J Neurophysiol. 1998;79(1):240-252. — In vitro electrophysiology study confirming ethosuximide's T-type calcium channel mechanism, retrieved via OpenAlex's single-record PMID lookup (this endpoint worked reliably when the bulk search endpoints did not) Used only as pharmacology/mechanism context for ethosuximide's own intended target; this is the drug's labeled pharmacology (Hard Rule 2), not nutrient evidence, and is not graded.Used only as pharmacology/mechanism context for ethosuximide's own intended target; this is the drug's labeled pharmacology (Hard Rule 2), not nutrient evidence, and is not graded.
  11. Wikipedia, "Ethosuximide," synthesizing DrugBank entry DB00593 — Secondary tertiary source used for granular pharmacokinetic parameters (bioavailability ~93%, half-life ~53 hours, CYP3A4/CYP2E1 metabolism, ~20% renal excretion unchanged) not stated with that level of detail in ethosuximide's own FDA label text available this session; DrugBank's own public page required a login for the equivalent detail, and accessdata.fda.gov and a direct DrugBank fetch of DB00593 both failed or returned the wrong record this session
  12. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, N03AD01 (ethosuximide) — ATC classification Access note: cited per the Wikipedia/DrugBank synthesis above; a direct fetch of atcddd.fhi.no to independently re-verify the code this session returned a 429 rate-limit response.Access note: cited per the Wikipedia/DrugBank synthesis above; a direct fetch of atcddd.fhi.no to independently re-verify the code this session returned a 429 rate-limit response.
  13. Shahar E, et al. Aplastic anemia following therapy for absence seizures with ethosuximide. 1994. — Case report, ethosuximide specifically named. Found and read this revision via a completed PubMed search-listing page ("ethosuximide hemoglobin OR ethosuximide anemia OR ethosuximide erythropoiesis"). Describes a direct hematologic toxicity, not a nutrient-status finding; used only to corroborate the label's blood-dyscrasia warning in the Monitoring panel, per Hard Rule 2, not graded as a nutrient entry.
  14. Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone. 1983. — Case report, ethosuximide specifically named. Found and read this revision via the same completed PubMed search as above. Same use and limitation as the Shahar et al. 1994 case report.
  15. Ethosuximide-associated Aplastic Anemia Likely Due to Drug-induced Lupus Erythematosus: A Case Report With Immunologic Insights. 2025. — Case report, ethosuximide specifically named, proposing a drug-induced-lupus mechanism for the bone-marrow toxicity. Found and read this revision via the same completed PubMed search as above. Same use and limitation as the other two aplastic-anemia case reports.